Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Modalis Therapeutics Corporation

News headline image
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
From Modalis Therapeutics Corporation
Via Business Wire
News headline image
Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
From Modalis Therapeutics Corporation
Via Business Wire
News headline image
JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
From Modalis Therapeutics Corporation
Via Business Wire
News headline image
Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).
From Modalis Therapeutics Corporation
Via Business Wire
News headline image
Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)
From Modalis Therapeutics Corporation
Via Business Wire
News headline image
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
From Modalis Therapeutics Corporation
Via Business Wire
News headline image
Modalis Announces Partnership with Ginkgo Bioworks
From Modalis Therapeutics Corporation
Via Business Wire
News headline image
Modalis and JCR Pharmaceuticals enter into joint research agreement
From Modalis Therapeutics Corporation
Via Business Wire
News headline image
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting
From Modalis Therapeutics Corporation
Via Business Wire
News headline image
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular Dystrophy and the Other Genetic Disorders at the ASGCT Annual Meeting
From Modalis Therapeutics Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.